Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
Status:
Unknown status
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
To compare the rate and extent of absorption of Aripiprazole Orally disintegrating tablets 10
mg of Chengdu Kanghong Pharmaceutical Group Co.,Ltd, China and ABILIFY (Aripiprazole) 10 mg
orodispersible tablets of Otsuka Pharmaceutical Europe Ltd. in healthy, adult, human subjects
under fasting/fed condition as well as to monitor the safety and tolerability of subjects.